CTF1 and Fabry disease: In conclusion, CT-1 can probably be considered a good biomarker to monitor the progression of hypertension with age in association with left ventricular hypertrophy [21], but particular attention is needed when monitoring the development of hypertension in FD patients, where CT-1 does not correlate with this disease.